肺動脈性肺高血圧症(PAH)の世界市場インサイト・疫学分析・市場予測

DelveInsightが発行した調査報告書(DELV803015)
◆英語タイトル:Pulmonary Arterial Hypertension (PAH) Market Insight, Epidemiology and Market Forecast
◆商品コード:DELV803015
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:100
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD6,250 ⇒換算¥706,250見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD12,500 ⇒換算¥1,412,500見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD18,750 ⇒換算¥2,118,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Pulmonary Arterial Hypertension (PAH) – Disease Understanding and Treatment Algorithm
The DelveInsight Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the Pulmonary Arterial Hypertension (PAH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the US, Europe, and Japan.

Pulmonary Arterial Hypertension (PAH) Epidemiology
The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, and sub-type specific prevalent cases) scenario of Pulmonary Arterial Hypertension (PAH)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of prevalent population of Pulmonary Arterial Hypertension (PAH) was found to be more than 70,000 in 7MM, in the year 2016. Women account for 70% of the total prevalent cases.

Pulmonary Arterial Hypertension (PAH) Drug Chapters
This segment of the Pulmonary Arterial Hypertension (PAH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Therapeutic market of PAH is dominated with the use of endothelin receptor antagonists, prostanoids, calcium channel blockers, phosphodiesterase inhibitors and Soluble Guanylate Cyclase (sGC) stimulators. Detailed chapters of all these therapies, along with the upcoming therapies such as Aurora-GT ((United Therapeutics Corp.), Tysuberprost (United Therapeutics Corp.) and Macitentan (Actelion Pharmaceuticals Ltd) have been covered in the report.

Pulmonary Arterial Hypertension (PAH) Market Outlook
The Pulmonary Arterial Hypertension (PAH) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be USD 5.13 Billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.

Pulmonary Arterial Hypertension (PAH) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pulmonary Arterial Hypertension (PAH) Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Pulmonary Arterial Hypertension (PAH) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Pulmonary Arterial Hypertension (PAH) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market
• Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) market
• To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market.

【レポートの目次】

1. Report Introduction
2. Pulmonary Arterial Hypertension Market Overview at a Glance
2.1. Global Market Share Distribution of Pulmonary Arterial Hypertension in 2016
2.2. Global Market Share Distribution of Pulmonary Arterial Hypertension in 2027
3. Pulmonary Arterial Hypertension (PAH): Overview
3.1. Signs and Symptoms
3.2. Classification of Pulmonary Arterial Hypertension (PAH)
3.3. Functional Classification of PAH
3.4. Etiology
3.5. Risk factors
3.6. Pathophysiology
3.7. Diagnosis
3.8. Treatment
4. Epidemiology and Patient Population
4.1. Key Points
4.2. Population and Forecast Parameters
4.3. Prevalent Population of Pulmonary Arterial Hypertension (PAH) in 7MM
4.3.1. United States
4.3.1.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.1.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.1.3. Gender Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.2. Germany
4.3.2.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.2.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.2.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.3. France
4.3.3.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.3.2. Sub-type Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.3.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.4. Italy
4.3.4.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.4.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.4.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.5. Spain
4.3.5.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.5.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.5.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.6. United Kingdom
4.3.6.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.6.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.6.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.7. Japan
4.3.7.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.7.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.7.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
5. Treatment Algorithm
5.1. United States
5.1.1. CHEST Guidelines
5.2. Europe
5.2.1. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines
6. Unmet Needs
7. Marketed Products
7.1. Approval and Market Presence
7.2. Company-Wise Marketed Products
7.2.1. United Therapeutics Corporation
7.2.1.1. Comparative Analysis of Marketed Therapies
7.2.1.1.1.1. Mechanism of action
7.2.1.1.1.2. Regulatory Milestones
7.2.1.1.1.3. Safety and efficacy profiles
7.2.1.1.1.4. Side effects
7.2.1.1.1.5. Product profile
7.2.2. Actelion Pharmaceuticals Ltd.
7.2.2.1. Comparative Analysis of Marketed Therapies
7.2.2.1.1.1. Mechanism of action
7.2.2.1.1.2. Regulatory Milestones
7.2.2.1.1.3. Safety and efficacy profiles
7.2.2.1.1.4. Side effects
7.2.2.1.1.5. Product profile
7.2.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
7.2.3.1. Comparative Analysis of Marketed Therapies
7.2.3.1.1.1. Mechanism of action
7.2.3.1.1.2. Regulatory Milestones
7.2.3.1.1.3. Safety and efficacy profiles
7.2.3.1.1.4. Side effects
7.2.3.1.1.5. Product profile
7.2.4. Bayer AG
7.2.4.1. Comparative Analysis of Marketed Therapies
7.2.4.1.1.1. Mechanism of action
7.2.4.1.1.2. Regulatory Milestones
7.2.4.1.1.3. Safety and efficacy profiles
7.2.4.1.1.4. Side effects
7.2.4.1.1.5. Product profile
7.2.5. Pfizer
7.2.5.1. Comparative Analysis of Marketed Therapies
7.2.5.1.1.1. Mechanism of action
7.2.5.1.1.2. Regulatory Milestones
7.2.5.1.1.3. Safety and efficacy profiles
7.2.5.1.1.4. Side effects
7.2.5.1.1.5. Product profile
8. Emerging Therapies
8.1. Tysuberprost: United Therapeutics Corporation
8.1.1. Regulatory Milestones
8.1.2. Clinical Development
8.1.3. Product Profile
8.1.4. Clinical Pipeline Activity
8.1.4.1. Ongoing Trials Information
8.1.4.2. Clinical Trial by Phase
8.2. Aurora GT: United Therapeutics Corporation
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. Macitentan: Actelion Pharmaceuticals Ltd.
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.3.4.2. Clinical Trial by Phase
9. Pulmonary Arterial Hypertension (PAH) Market Size
9.1. Key Findings
9.2. Global Market Outlook: Pulmonary Arterial Hypertension (PAH)
9.2.1. Assumptions and Forecast Parameters
9.2.2. Global Market Analysis
9.3. Total 7MM Pulmonary Arterial Hypertension (PAH) Market Analysis
9.3.1. Overview of Total Pulmonary Arterial Hypertension (PAH)Market (2016-2027)
9.4. Region-Wise Market Analysis
9.4.1. United States Market Size
9.4.1.1. Assumptions
9.4.1.2. Market Analysis
9.4.1.3. Emerging therapies analysis: Impact on the market
9.4.2. Europe Market Size
9.4.2.1. Assumptions and Forecast Parameters
9.4.2.2. Germany Market Size
9.4.2.2.1.1. Market Analysis
9.4.2.2.1.2. Emerging therapies analysis: Impact on the market
9.4.2.3. France Market Size
9.4.2.3.1.1. Market Analysis
9.4.2.3.1.2. Emerging therapies analysis: Impact on the market
9.4.2.4. United Kingdom Market Size
9.4.2.4.1. Market Analysis
9.4.2.4.2. Emerging therapies analysis: Impact on the market
9.4.2.5. Spain Market Size
9.4.2.5.1. Market Analysis
9.4.2.5.2. Emerging therapies analysis: Impact on the market
9.4.2.6. Italy Market Size
9.4.2.6.1. Market Analysis
9.4.2.6.2. Emerging therapies analysis: Impact on the market
9.4.3. Rest of Europe (ROE) Market Size
9.4.3.1. Assumptions
9.4.3.2. Market Analysis
9.4.3.3. Emerging therapies analysis: Impact on the market
9.4.4. Japan Market Size
9.4.4.1. Assumptions
9.4.4.2. Market Analysis
9.4.4.3. Emerging therapies analysis: Impact on the market
9.4.5. Rest of World (ROW) Market Size
9.4.5.1. Assumptions
9.4.5.2. Market Analysis
9.4.5.3. Emerging therapies analysis: Impact on the market
10. Market Drivers
11. Market Barriers
12. Report Methodology
12.1. Sources Used
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight

Table 1: Total Prevalent Population of PAH in 7 MM (2016-2027)
Table 2: Prevalent Population of PAH in United States (2016-2027)
Table 3: Sub-type Specific Population of PAH in United States (2016-2027)
Table 4: Gender Specific Population of PAH in United States (2016-2027)
Table 5: Prevalent Population of PAH in Germany (2016-2027)
Table 6: Sub-type Specific Population of PAH in Germany (2016-2027)
Table 7: Gender Specific Population of PAH in Germany (2016-2027)
Table 8: Prevalent Population of PAH in France (2016-2027)
Table 9: Sub-type Specific Population of PAH in France (2016-2027)
Table 10: Gender Specific Population of PAH in France (2016-2027)
Table 11: Prevalent Population of PAH in Italy (2016-2027)
Table 12: Sub-type Specific Population of PAH in Italy (2016-2027)
Table 13: Gender Specific Population of PAH in Italy (2016-2027)
Table 14: Prevalent Population of PAH in Spain (2016-2027)
Table 15: Sub-type Specific Prevalent Population of PAH in Spain (2016-2027)
Table 16: Gender Specific Population of PAH in Spain (2016-2027)
Table 17: Prevalent Population of PAH in United Kingdom (2016-2027)
Table 18: Sub-type Specific Population of PAH in United Kingdom (2016-2027)
Table 19: Gender Specific Population of PAH in United Kingdom (2016-2027)
Table 20: Prevalent Population of PAH in Japan (2016-2027)
Table 21: Sub-type Specific Population of PAH in Japan (2016-2027)
Table 22: Gender Specific Population of PAH in Japan (2016-2027)
Table 23: Marketed Drugs for Pulmonary Arterial Hypertension - Approval and Market presence
Table 24: Marketed Drugs developed by United Therapeutics Corporation
Table 25: Marketed Drugs developed by Actelion Pharmaceuticals Ltd.
Table 26: Marketed Drugs developed by GlaxoSmithKline Pharmaceuticals/ Gilead Sciences
Table 27: Marketed Drugs developed by Bayer (AG)
Table 28: Marketed Drugs developed by Pfizer
Table 29: Safety and Efficacy of Marketed Drugs
Table 30: Emerging therapies for the treatment of PAH
Table 31:Tysuberprost, Clinical Trials by Recruitment status, 2017
Table 32:Aurora GT, Clinical Trials by Recruitment status, 2017
Table 33:Macitentan:, Clinical Trials by Recruitment status, 2017
Table 34: Global Market Size of PAH in USD Million (2016-2027)
Table 35: 7 Major Market Size of PAH in USD Million (2016-2027)
Table 36: Market Size of PAH in United States, USD Million (2016-2027)
Table 37: Market Size of PAH in Germany, USD Million (2016-2027)
Table 38: Market Size of PAH in France, USD Million (2016-2027)
Table 39: Market Size of PAH in Italy, USD Million (2016-2027)
Table 40: Market Size of PAH in Spain, USD Million (2016-2027)
Table 41: Market Size of PAH in United Kingdom, USD Million (2016-2027)
Table 42: Market Size of PAH in Rest of Europe (ROE), USD Million (2016-2027)
Table 43: Market Size of PAH in Japan, USD Million (2016-2027)
Table 44: Market Size of PAH in Rest of World (ROW), USD Million (2016-2027)


Figure 1: Classification of Pulmonary Arterial Hypertension (PAH)
Figure 2: Functional Classification of PAH
Figure 3:Risk Factors of Pulmonary Arterial Hypertension
Figure 4: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
Figure 5: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 6: Treatment Options for Pulmonary Arterial Hypertension (PAH)
Figure 7: Prevalent Population Of PAH in 7 MM (2016-2027)
Figure 8: Prevalent Population of PAH in United States (2016-2027)
Figure 9: Sub-type Specific Prevalent Population of PAH in United States (2016-2027)
Figure 10: Gender Specific Prevalent Population of PAH in United States (2016-2027)
Figure 11: Prevalent Population of PAH in Germany (2016-2027)
Figure 12: Sub-type Specific Prevalent Population of PAH in Germany (2016-2027)
Figure 13: Gender Specific Prevalent Population of PAH in Germany (2016-2027)
Figure 14: Prevalent Population of PAH in France (2016-2027)
Figure 15: Sub-type Specific Prevalent Population of PAH in France (2016-2027)
Figure 16: Gender Specific Prevalent Population of PAH in France (2016-2027)
Figure 17: Prevalent Population of PAH in Italy (2016-2027)
Figure 18: Sub-type Specific Prevalent Population of PAH in Italy (2016-2027)
Figure 19: Gender Specific Prevalent Population of PAH in Italy (2016-2027)
Figure 20: Prevalent Population of PAH in Spain (2016-2027)
Figure 21: Sub-type Specific Prevalent Population of PAH in Spain (2016-2027)
Figure 22: Gender Specific Prevalent Population of PAH in Spain (2016-2027)
Figure 23: Prevalent Population of PAH in United Kingdom (2016-2027)
Figure 24: Sub-type Specific Prevalent Population of PAH in United Kingdom (2016-2027)
Figure 25: Gender Specific Prevalent Population of PAH in United Kingdom (2016-2027)
Figure 26: Prevalent Population of PAH in Japan (2016-2027)
Figure 27: Sub-type Specific Prevalent Population of PAH in Japan (2016-2027)
Figure 28: Gender Specific Prevalent Population of PAH in Japan (2016-2027)
Figure 29: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 30: Global Market Size of PAH in USD Million (2016-2027)
Figure 31: 7 Major Market size of PAH in USD Million (2016-2027)
Figure 32: Market Size of PAH in United States, USD Million (2016-2027)
Figure 33: Market Size of PAH in Germany, USD Million (2016-2027)
Figure 34: Market Size of PAH in France, USD Million (2016-2027)
Figure 35: Market Size of PAH in Italy, USD Million (2016-2027)
Figure 36: Market Size of PAH in Spain, USD Million (2016-2027)
Figure 37: Market Size of PAH in United Kingdom, USD Million (2016-2027)
Figure 38: Market Size of PAH in Rest of Europe (ROE), USD Million (2016-2027)
Figure 39: Market Size of PAH in Japan, USD Million (2016-2027)
Figure 40: Market Size of PAH in Rest of World (ROW), USD Million (2016-2027)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肺動脈性肺高血圧症(PAH)の世界市場インサイト・疫学分析・市場予測(Pulmonary Arterial Hypertension (PAH) Market Insight, Epidemiology and Market Forecast )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆